Conor C Lynch
Despite medical advances, the American Cancer Society predicts that approximately 30,000 men will succumb to prostate cancer during 2012 in the United States alone. The majority of these men will die from metastatic burden. Bone metastasis is a common event in prostate cancer progression with the resultant lesions severely impacting the patient’s quality of life. In collaboration with the clinicians and physician scientists in Genitourinary Oncology at the Moffitt Cancer Center, we are focused on identifying the molecular mechanisms underlying prostate cancer metastasis and prostate cancer induced changes in the bone microenvironment. To this end, we incorporate a number of pre-clinical animal models that recapitulate the pathophysiology of human prostate to bone metastasis. We are also interested in testing a number of small molecule inhibitors in these models. My group has extensisive experience in prostate cancer progression, bone imaging and in bone histology/histomorphometry. We are 100% dedicated to identifying new therapies and treatment strategies that will effectively treat men with advanced prostate cancer.
For more info on me and my lab, please visit us at;
Abstracts this author is presenting: